Literature DB >> 7961974

Binding of the nicotinic acetylcholine receptor to SH2 domains of Fyn and Fyk protein tyrosine kinases.

S L Swope1, R L Huganir.   

Abstract

The nicotinic acetylcholine receptor (AChR) is phosphorylated on tyrosine both in vitro and in vivo. To identify the protein tyrosine kinase that phosphorylates the receptor, we have previously cloned and characterized two protein tyrosine kinases, Fyn and Fyk, that are highly expressed in Torpedo electric organ, a tissue enriched in the AChR. Both kinases were shown by coimmunoprecipitation to be specifically associated with the AChR. In this study, we examined the molecular basis for the interaction of Fyn and Fyk with the AChR using fusion proteins containing the SH2 domains of the two kinases as affinity reagents. The AChR bound specifically and in a protein concentration-dependent manner to the SH2 domain fusion proteins of Fyn and Fyk. Quantitation of the association revealed that the binding of the AChR to Fyn and Fyk SH2 domain fusion proteins was to a single class of saturable high affinity sites. In addition, the association of the AChR with the SH2 domain fusion proteins was dependent on tyrosine phosphorylation of the AChR and was mediated by the delta subunit of the receptor. Furthermore, upon dissociation of the AChR into subunits, the delta subunit coimmunoprecipitated with both Fyn and Fyk. These data suggest that the association of the AChR with Fyn and Fyk is mediated by an interaction of the tyrosine-phosphorylated delta subunit of the receptor with the SH2 domains of the protein tyrosine kinases.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7961974

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

1.  Roles of rapsyn and agrin in interaction of postsynaptic proteins with acetylcholine receptors.

Authors:  C Fuhrer; M Gautam; J E Sugiyama; Z W Hall
Journal:  J Neurosci       Date:  1999-08-01       Impact factor: 6.167

2.  Regulation of neuregulin-mediated acetylcholine receptor synthesis by protein tyrosine phosphatase SHP2.

Authors:  M Tanowitz; J Si; D H Yu; G S Feng; L Mei
Journal:  J Neurosci       Date:  1999-11-01       Impact factor: 6.167

Review 3.  Clustering of nicotinic acetylcholine receptors: from the neuromuscular junction to interneuronal synapses.

Authors:  Kyung-Hye Huh; Christian Fuhrer
Journal:  Mol Neurobiol       Date:  2002-02       Impact factor: 5.590

4.  Src-class kinases act within the agrin/MuSK pathway to regulate acetylcholine receptor phosphorylation, cytoskeletal anchoring, and clustering.

Authors:  A S Mohamed; K A Rivas-Plata; J R Kraas; S M Saleh; S L Swope
Journal:  J Neurosci       Date:  2001-06-01       Impact factor: 6.167

5.  Slow, reversible, coupled folding and binding of the spectrin tetramerization domain.

Authors:  S L Shammas; J M Rogers; S A Hill; J Clarke
Journal:  Biophys J       Date:  2012-11-20       Impact factor: 4.033

6.  Association of muscle-specific kinase MuSK with the acetylcholine receptor in mammalian muscle.

Authors:  C Fuhrer; J E Sugiyama; R G Taylor; Z W Hall
Journal:  EMBO J       Date:  1997-08-15       Impact factor: 11.598

7.  Tyrosine phosphorylation of nicotinic acetylcholine receptor mediates Grb2 binding.

Authors:  M Colledge; S C Froehner
Journal:  J Neurosci       Date:  1997-07-01       Impact factor: 6.167

Review 8.  Intercellular communication that mediates formation of the neuromuscular junction.

Authors:  M P Daniels
Journal:  Mol Neurobiol       Date:  1997-06       Impact factor: 5.590

9.  Stimulation of nAchRα7 Receptor Inhibits TNF Synthesis and Secretion in Response to LPS Treatment of Mast Cells by Targeting ERK1/2 and TACE Activation.

Authors:  F Guzmán-Mejía; C López-Rubalcava; C González-Espinosa
Journal:  J Neuroimmune Pharmacol       Date:  2017-08-18       Impact factor: 4.147

10.  Constitutive activation of delayed-rectifier potassium channels by a src family tyrosine kinase in Schwann cells.

Authors:  A Sobko; A Peretz; B Attali
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.